account_id none on file
legal_name Starling Oncology, Inc.
ticker TOI
cik 1799191
domain theoncologyinstitute.com
linkedin_company_url https://www.linkedin.com/company/oncologyinstitute
entry_point_account_id none on file
name The Oncology Institute Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 5 executives 2 family 0
why_nownone on file
callsnone on file
filings
As a percentage of revenue, SG&A decreased 390 basis points for the three months ended June 30, 2026 as compared to the same period in the prior year which reflected the operating leverage built into the model as the Company's continues to scale, along with cost discipline.
filing / Aug 6, 2026 / receipt
(4) Infrastructure and workforce costs were primarily comprised of recruiting expenses to build out corporate infrastructure of $305 and $150, severance expenses resulting from cost rationalization programs of $15 and $49, stop-loss contract timing of approximately $0 and $1,099, and reversal of settlements of $165 and $487 during the three months ended June 30, 2026 and 2025, respectively.
filing / Aug 6, 2026 / receipt
(4) Infrastructure and workforce costs were primarily comprised of recruiting expenses to build out corporate infrastructure of $476 and $150, severance expenses resulting from cost rationalization programs of $257 and $49, stop-loss contract timing of approximately $1 and $1,099, and legal costs related to infrastructure build out and settlements of $172 and $487, partially offset by EOM/CMS performance period non-r
filing / Aug 6, 2026 / receipt
(4) Infrastructure and workforce costs were comprised of recruiting expenses to build out corporate infrastructure of $169 and $277, severance expenses resulting from cost rationalization programs of $242 and $140, stop-loss contract timing of approximately $1 and $0, EOM/CMS performance period non-recurring addback of $818 and $0, and non-recurring legal fees related to infrastructure build out and settlements of $3
filing / May 7, 2026 / receipt
If the Company cannot generate or obtain needed funds, it might be forced to make substantial reductions in its operating and capital expenses or pursue restructuring plans, which could adversely affect its business operations and ability to execute its current business strategy.
filing / May 7, 2026 / receipt
executives
| Daniel Virnich | Chief Executive Officer | - | receipt |
| Jeremy N. Castle | Chief Operations Officer | - | receipt |
familynone on file
upcomingnone on file
changes
| 2023-09-06 | Chief Operations Officer, appointed | sec_8k |
| 2023-06-14 | Chief Executive Officer, appointed | sec_8k |
| 2023-06-12 | Chief Executive Officer, appointed | sec_8k |
| 2022-03-07 | President, appointed | sec_8k |
mcp_package_hint
slug the-oncology-institute-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$